Bausch + Lomb Announces Statistically Significant Topline Results From The Second Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With Meibomian Gland Dysfunction; Co. Reports ‘All Primary and Secondary Endpoints Were Achieved’
B
ausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focusing on first- and
